These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36123181)

  • 61. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
    Tovar-Parra D; Gil-Quiñones SR; Nova J; Gutiérrez-Castañeda LD
    In Vivo; 2021; 35(3):1529-1536. PubMed ID: 33910831
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.
    Jones R; Ruas M; Gregory F; Moulin S; Delia D; Manoukian S; Rowe J; Brookes S; Peters G
    Cancer Res; 2007 Oct; 67(19):9134-41. PubMed ID: 17909018
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM).
    Noë M; Hackeng WM; de Leng WWJ; Vergeer M; Vleggaar FP; Morsink FHM; Wood LD; Hruban RH; Offerhaus GJA; Brosens LAA
    Am J Surg Pathol; 2019 Sep; 43(9):1297-1302. PubMed ID: 31261289
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Involvement of p16CDKN2A in cell cycle delays after low dose UV irradiation.
    Milligan A; Gabrielli BG; Clark JM; Hayward NK; Ellem KA
    Mutat Res; 1998 Nov; 422(1):43-53. PubMed ID: 9920427
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
    Kannengiesser C; Brookes S; del Arroyo AG; Pham D; Bombled J; Barrois M; Mauffret O; Avril MF; Chompret A; Lenoir GM; Sarasin A; ; Peters G; Bressac-de Paillerets B
    Hum Mutat; 2009 Apr; 30(4):564-74. PubMed ID: 19260062
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
    Tsao H; Benoit E; Sober AJ; Thiele C; Haluska FG
    Cancer Res; 1998 Jan; 58(1):109-13. PubMed ID: 9426066
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
    Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
    J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal.
    Castellano M; Gabrielli BG; Hussussian CJ; Dracopoli NC; Hayward NK
    J Invest Dermatol; 1997 Jul; 109(1):61-8. PubMed ID: 9204956
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
    Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
    Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
    Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
    Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline
    Helgadottir H; Ghiorzo P; van Doorn R; Puig S; Levin M; Kefford R; Lauss M; Queirolo P; Pastorino L; Kapiteijn E; Potrony M; Carrera C; Olsson H; Höiom V; Jönsson G
    J Med Genet; 2020 May; 57(5):316-321. PubMed ID: 30291219
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Frequent p16-independent inactivation of p14ARF in human melanoma.
    Freedberg DE; Rigas SH; Russak J; Gai W; Kaplow M; Osman I; Turner F; Randerson-Moor JA; Houghton A; Busam K; Timothy Bishop D; Bastian BC; Newton-Bishop JA; Polsky D
    J Natl Cancer Inst; 2008 Jun; 100(11):784-95. PubMed ID: 18505964
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
    Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
    Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lack of germline CDK6 mutations in familial melanoma.
    Shennan MG; Badin AC; Walsh S; Summers A; From L; McKenzie M; Goldstein AM; Tucker MA; Hogg D; Lassam N
    Oncogene; 2000 Mar; 19(14):1849-52. PubMed ID: 10777219
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
    Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N;
    J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The INK4a/ARF locus and melanoma.
    Sharpless E; Chin L
    Oncogene; 2003 May; 22(20):3092-8. PubMed ID: 12789286
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Novel CDKN2A mutation detected in Spanish melanoma pedigree.
    de Torre C; Martínez-Escribano J
    Exp Dermatol; 2010 Aug; 19(8):e333-5. PubMed ID: 20653773
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Germline CDKN2A mutation implicated in predisposition to multiple myeloma.
    Dilworth D; Liu L; Stewart AK; Berenson JR; Lassam N; Hogg D
    Blood; 2000 Mar; 95(5):1869-71. PubMed ID: 10688850
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma.
    Hogg D; Brill H; Liu L; Monzon J; Summers A; From L; Lassam NJ
    J Cutan Med Surg; 1998 Jan; 2(3):172-9. PubMed ID: 9479083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.